Bosentan benefits in mild pulmonary arterial hypertension

kavin submitted, created time 6 months 1 week (www.thelancet.com)

The EARLY study, published in the June 21, 2008 issue of the Lancet, was conducted by a group led by Dr Nazzareno Galiè (University of Bologna, Italy).

They note that bosentan has been shown to improve exercise capacity, hemodynamics, and delay clinical worsening in two pivotal clinical trials, but in these, like other trials of treatments for pulmonary arterial hypertension, the vast majority of enrolled patients were in an advanced symptomatic state (WHO functional class 3 and 4)

3 comments | Blog It | Email It | Keywords: hemosynamics hypertension Bosentan pulmonary arterial hypertension Pulmonary Ossification